Scott L. Burrows net worth and biography

Scott Burrows Biography and Net Worth

CFO of Spyre Therapeutics

Scott Burrows, M.B.A., is Chief Financial Officer. He is a veteran of the biopharma industry with more than two decades of diverse experience and a proven track-record in biopharmaceutical finance leadership roles spanning multiple public companies. Prior to Spyre, he served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he helped lead Arcutis through a successful initial public offering, several further equity and debt financings, and the transition to a fully integrated commercial-stage company. Prior to Arcutis, Mr. Burrows was the head of international investor relations for Shire, plc based in Switzerland. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury, and investor relations. Mr. Burrows began his career at Arthur Andersen as a consultant. He earned his B.A. and M.B.A. from the University of California, Los Angeles, and is a licensed CPA (inactive).

What is Scott L. Burrows' net worth?: The estimated net worth of Scott L. Burrows is at least $3.29 million as of September 2nd, 2025. Mr. Burrows owns 97,994 shares of Spyre Therapeutics stock worth more than $3,294,558 as of December 13th. This net worth evaluation does not reflect any other assets that Mr. Burrows may own. Additionally, Mr. Burrows receives an annual salary of $331,810.00 as CFO at Spyre Therapeutics. Learn More about Scott L. Burrows' net worth.
How old is Scott L. Burrows?: Mr. Burrows is currently 47 years old. There are 2 older executives and no younger executives at Spyre Therapeutics. Learn More on Scott L. Burrows' age.
What is Scott L. Burrows' salary?: As the CFO of Spyre Therapeutics, Inc., Mr. Burrows earns $331,810.00 per year. There are 2 executives that earn more than Mr. Burrows. The highest earning executive at Spyre Therapeutics is Dr. Cameron Turtle DPHIL, Ph.D., CEO & Director, who commands a salary of $674,170.00 per year. Learn More on Scott L. Burrows' salary.
How do I contact Scott L. Burrows?: The corporate mailing address for Mr. Burrows and other Spyre Therapeutics executives is 805 Las Cimas Parkway, Suite 100, Austin, TX 78746, United States. Spyre Therapeutics can also be reached via phone at 512-942-2935 and via email at [email protected]. Learn More on Scott L. Burrows' contact information.
Has Scott L. Burrows been buying or selling shares of Spyre Therapeutics?: Scott L. Burrows has not been actively trading shares of Spyre Therapeutics in the last ninety days. Most recently, Scott L. Burrows sold 18,428 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $16.26, for a transaction totalling $299,639.28. Following the completion of the sale, the chief financial officer now directly owns 97,994 shares of the company's stock, valued at $1,593,382.44. Learn More on Scott L. Burrows' trading history.
Who are Spyre Therapeutics' active insiders?: Spyre Therapeutics' insider roster includes Jeffrey Albers (Director), Scott Burrows (CFO), and Cameron Turtle (CEO). Learn More on Spyre Therapeutics' active insiders.
Are insiders buying or selling shares of Spyre Therapeutics?: In the last twelve months, insiders at the sold shares 3 times. They sold a total of 78,428 shares worth more than $1,784,789.28. The most recent insider tranaction occured on December, 1st when CEO Cameron Turtle sold 15,000 shares worth more than $435,300.00. Insiders at Spyre Therapeutics own 15.4% of the company. Learn More about insider trades at Spyre Therapeutics.
Information on this page was last updated on 12/1/2025.

Scott L. Burrows Insider Trading History at Spyre Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/2/2025	Sell	18,428	$16.26	$299,639.28	97,994

Scott L. Burrows Buying and Selling Activity at Spyre Therapeutics

Spyre Therapeutics Company Overview

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $33.62

$33.24

$35.17

50 Day Range

MA: $25.14

$16.02

$34.66

2 Week Range

Now: $33.62

$10.91

$35.31

Volume

724,273 shs

Average Volume

709,165 shs

Market Capitalization

$2.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.14

Scott Burrows Biography and Net Worth

What is Scott L. Burrows' net worth?

How old is Scott L. Burrows?

What is Scott L. Burrows' salary?

How do I contact Scott L. Burrows?

Has Scott L. Burrows been buying or selling shares of Spyre Therapeutics?

Who are Spyre Therapeutics' active insiders?

Are insiders buying or selling shares of Spyre Therapeutics?